Kelly-Anne Phillips.

Gelber, Ph.D., Gabriel N. Hortobagyi, M.D., and Kathy S. Albain, M.D. For the POEMS/S0230 Investigators: Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy Early ovarian failure can be an important and devastating long-term toxic aftereffect of chemotherapy potentially. Manifestations consist of menopausal symptoms, osteoporosis, and infertility. Worries about fertility might influence treatment selections for young women with breast cancer1,2 despite the known survival benefit of adjuvant chemotherapy. Trials of the coadministration of a gonadotropin-releasing hormone agonist with adjuvant chemotherapy for the purpose of protecting ovarian function show mixed outcomes.4 The usage of adjuvant endocrine therapy after chemotherapy complicates the assessment of longer-term ovarian function after administration of a GnRH agonist with chemotherapy., a biopharmaceutical organization focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, announced its unaudited financial outcomes for the first one fourth ended March 31 today, 2012. ACADIA reported a net lack of $6.2 million, or $0.12 per common share, for the first quarter of 2012 compared to a net loss of $5.8 million, or $0.12 per common talk about, for the first quarter of 2011. At March 31, 2012, ACADIA’s money, cash equivalents and expenditure securities totaled $25.9 million in comparison to $31.